BioNTech SE (BNTX) shares surged 5.15% in pre-market trading on Tuesday, following the announcement of a major cancer drug development deal with Bristol Myers Squibb. The agreement, which could be worth up to $11.1 billion, marks a significant milestone for the German biotech company best known for its Covid-19 vaccine.
Under the terms of the deal, BioNTech will receive an upfront payment of $1.5 billion and $2 billion in installments through 2028. Additionally, the company is eligible for up to $7.6 billion in development, regulatory, and commercial milestone payments. This partnership aims to accelerate the development of BioNTech's experimental cancer drug, potentially expanding its portfolio beyond Covid-19 vaccines.
The substantial deal highlights the growing interest in innovative cancer treatments and solidifies BioNTech's position in the oncology market. It also comes at a time when biotech companies are gaining renewed attention due to rising Covid-19 cases in several Asian countries. While BioNTech's Covid-19 vaccine remains a crucial part of its business, this cancer drug partnership demonstrates the company's commitment to diversifying its pipeline and leveraging its mRNA technology platform for other therapeutic areas.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。